{"transactions":[{"id":727421,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:16:55.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":181000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":25.19,"expiration_date":"2036-02-02","underlying":"Ordinary Shares","underlying_shares":181000},"source":{"system":"sec-edgar","filing":"0001470831-26-000620","document":"wk-form4_1782332212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000147083126000620/wk-form4_1782332212.xml","form_type":"4"}},{"id":727420,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:16:55.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":16.9,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001470831-26-000620","document":"wk-form4_1782332212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000147083126000620/wk-form4_1782332212.xml","form_type":"4"}},{"id":727419,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2026-06-24T20:16:55.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":600000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Transaction Agreement at the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive (i) an amount in cash equal to the excess of the Cash Consideration over the per-share exercise price of such option, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No share options were exercised prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":8.8,"expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001470831-26-000620","document":"wk-form4_1782332212.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000147083126000620/wk-form4_1782332212.xml","form_type":"4"}},{"id":727418,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:16:55.000Z","date":"2026-06-24","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F5","text":"Represents Ordinary Shares underlying Restricted Share Units (\"RSUs\"). Each RSU represented a contingent right to receive one Ordinary Share of the Company. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding and unvested RSU became fully vested, and at the Effective Time, each RSU was automatically cancelled and converted into the right to receive (i) $38.00 in cash per Ordinary Share underlying such RSU award, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No Ordinary Shares were issued upon settlement of RSUs prior to the Effective Time."},{"field":"shares","element":"transactionShares","label":"F5","text":"Represents Ordinary Shares underlying Restricted Share Units (\"RSUs\"). Each RSU represented a contingent right to receive one Ordinary Share of the Company. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding and unvested RSU became fully vested, and at the Effective Time, each RSU was automatically cancelled and converted into the right to receive (i) $38.00 in cash per Ordinary Share underlying such RSU award, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No Ordinary Shares were issued upon settlement of RSUs prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents Ordinary Shares underlying Restricted Share Units (\"RSUs\"). Each RSU represented a contingent right to receive one Ordinary Share of the Company. Pursuant to the Transaction Agreement, at the Effective Time, each outstanding and unvested RSU became fully vested, and at the Effective Time, each RSU was automatically cancelled and converted into the right to receive (i) $38.00 in cash per Ordinary Share underlying such RSU award, without interest and less applicable withholding taxes, and (ii) one CVR per underlying Ordinary Share, in each case in accordance with the Transaction Agreement. No Ordinary Shares were issued upon settlement of RSUs prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001470831-26-000620","document":"wk-form4_1782332212.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000147083126000620/wk-form4_1782332212.xml","form_type":"4"}},{"id":921105,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2026-02-04T00:02:43.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":181000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":181000,"derivative":{"exercise_price":25.19,"expiration_date":"2036-02-02","underlying":"Ordinary Shares","underlying_shares":181000},"source":{"system":"sec-edgar","filing":"0001470831-26-000096","document":"wk-form4_1770163360.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000147083126000096/wk-form4_1770163360.xml","form_type":"4"}},{"id":921104,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-04T00:02:43.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares reported in this transaction represent Restricted Share Units (\"RSUs\") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001470831-26-000096","document":"wk-form4_1770163360.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000147083126000096/wk-form4_1770163360.xml","form_type":"4"}},{"id":1283772,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2025-02-04T21:57:38.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 3, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":250000,"derivative":{"exercise_price":16.9,"expiration_date":"2035-02-03","underlying":"Ordinary Shares","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001847903-25-000029","document":"wk-form4_1738706252.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000184790325000029/wk-form4_1738706252.xml","form_type":"4"}},{"id":1462107,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Share Option (right to buy)","published_at":"2024-07-02T20:30:32.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to such option shall vest and become exercisable on July 1, 2025 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":600000,"derivative":{"exercise_price":8.8,"expiration_date":"2034-07-01","underlying":"Ordinary Shares","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001847903-24-000114","document":"wk-form4_1719952224.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1587972/000184790324000114/wk-form4_1719952224.xml","form_type":"4"}},{"id":1492540,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":63700,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each RSU, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for, (i) if held by a Canadian Incentive Holder (as defined in the Arrangement Agreement), the number of Shares underlying such RSU and (ii) if held by a Non-Canadian Incentive Holder (as defined in the Arrangement Agreement), (A) a cash payment by or on behalf of the Issuer equal to the number of Shares underlying such RSU multiplied by the amount, if any, by the Cash Consideration and (B) one CVR with respect to each Share underlying such RSU, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each RSU, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for, (i) if held by a Canadian Incentive Holder (as defined in the Arrangement Agreement), the number of Shares underlying such RSU and (ii) if held by a Non-Canadian Incentive Holder (as defined in the Arrangement Agreement), (A) a cash payment by or on behalf of the Issuer equal to the number of Shares underlying such RSU multiplied by the amount, if any, by the Cash Consideration and (B) one CVR with respect to each Share underlying such RSU, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each RSU, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for, (i) if held by a Canadian Incentive Holder (as defined in the Arrangement Agreement), the number of Shares underlying such RSU and (ii) if held by a Non-Canadian Incentive Holder (as defined in the Arrangement Agreement), (A) a cash payment by or on behalf of the Issuer equal to the number of Shares underlying such RSU multiplied by the amount, if any, by the Cash Consideration and (B) one CVR with respect to each Share underlying such RSU, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":63700},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492539,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":313359,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":2.19,"underlying":"Common Stock","underlying_shares":313359},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492538,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":106100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":8.44,"underlying":"Common Stock","underlying_shares":106100},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492537,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":3.75,"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492536,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":167000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":7.7,"underlying":"Common Stock","underlying_shares":167000},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492535,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":138000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":11.9,"underlying":"Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492534,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60852,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Stock","underlying_shares":60852},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492533,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26972,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":17,"underlying":"Common Stock","underlying_shares":26972},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492532,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38561,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an \"Option\") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"derivative":{"exercise_price":2.99,"underlying":"Common Stock","underlying_shares":38561},"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1492531,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-06-04T17:26:47.000Z","date":"2024-06-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10410,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the \"Arrangement Agreement\"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden (\"Parent\") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act (\"Purchaser\"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the \"Shares\") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the \"Effective Time\"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the \"Cash Consideration\") plus (ii) one contingent value right (each, a \"CVR\") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-068893","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024068893/ownership.xml","form_type":"4"}},{"id":1685593,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-05T08:52:41.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":63700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027."}],"balance_after":63700,"derivative":{"underlying":"Common Stock","underlying_shares":63700},"source":{"system":"sec-edgar","filing":"0000950170-24-002299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024002299/ownership.xml","form_type":"4"}},{"id":1685592,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-05T08:52:41.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":106100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 equal monthly installments beginning on February 4, 2024."}],"balance_after":106100,"derivative":{"exercise_price":8.44,"expiration_date":"2034-01-04","underlying":"Common Stock","underlying_shares":106100},"source":{"system":"sec-edgar","filing":"0000950170-24-002299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000095017024002299/ownership.xml","form_type":"4"}},{"id":2058970,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-09T06:44:05.000Z","date":"2023-01-05","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests in 48 equal monthly installments beginning on February 5, 2023."}],"balance_after":250000,"derivative":{"exercise_price":3.75,"expiration_date":"2033-01-04","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-23-002496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919123002496/doc4.xml","form_type":"4"}},{"id":2414247,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-03T19:37:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":167000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in 48 equal monthly installments beginning on March 1, 2022."}],"balance_after":167000,"derivative":{"exercise_price":7.7,"expiration_date":"2032-02-01","underlying":"Common Stock","underlying_shares":167000},"source":{"system":"sec-edgar","filing":"0001209191-22-007050","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122007050/doc4.xml","form_type":"4"}},{"id":2414246,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-02-03T19:37:24.000Z","date":"2021-08-31","kind":"grant","acquired":true,"shares":3910,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were purchased pursuant to the issuer's 2020 Employee Stock Purchase Plan."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were purchased pursuant to the issuer's 2020 Employee Stock Purchase Plan."}],"balance_after":10410,"source":{"system":"sec-edgar","filing":"0001209191-22-007050","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000120919122007050/doc4.xml","form_type":"4"}},{"id":2874712,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-08T21:27:19.000Z","date":"2021-02-04","kind":"grant","acquired":true,"shares":138000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":138000,"derivative":{"exercise_price":11.9,"expiration_date":"2031-02-03","underlying":"Common Stock","underlying_shares":138000},"source":{"system":"sec-edgar","filing":"0000899243-21-005337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924321005337/doc4.xml","form_type":"4"}},{"id":3092442,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-07-02T16:04:01.000Z","date":"2020-06-30","kind":"purchase","acquired":true,"shares":6500,"price":17,"value":110500.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0000899243-20-018259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320018259/doc4.xml","form_type":"4"}},{"id":3096769,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:46:17.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":60852,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest and become exercisable on June 25, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":60852,"derivative":{"exercise_price":17,"expiration_date":"2030-06-25","underlying":"Common Shares","underlying_shares":60852},"source":{"system":"sec-edgar","filing":"0000899243-20-017883","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017883/doc4.xml","form_type":"4"}},{"id":3096768,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:46:17.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":26972,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option shall vest and become exercisable on June 18, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":26972,"derivative":{"exercise_price":17,"expiration_date":"2030-06-18","underlying":"Common Shares","underlying_shares":26972},"source":{"system":"sec-edgar","filing":"0000899243-20-017883","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017883/doc4.xml","form_type":"4"}},{"id":3096767,"issuer":{"id":11851,"kind":"organization","name":"Fusion Pharmaceuticals Inc.","symbol":"FUSN"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-30T06:46:17.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":38561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on January 10, 2021, with the remainder vesting in 36 substantially equal monthly installments thereafter. Prior to closing of the Issuer's initial public offering, such Non-Voting Common Shares will convert into Voting Common Shares and subsequently into Common Shares on a one-for-one basis."}],"balance_after":38561,"derivative":{"exercise_price":2.99,"expiration_date":"2030-01-10","underlying":"Non-Voting Common Shares","underlying_shares":38561},"source":{"system":"sec-edgar","filing":"0000899243-20-017883","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805890/000089924320017883/doc4.xml","form_type":"4"}},{"id":4587635,"issuer":{"id":3398,"kind":"organization","name":"CHARLES RIVER LABORATORIES INTERNATIONAL, INC.","symbol":"CRL"},"owners":[{"id":35601,"kind":"person","name":"Crowley John J","position":1,"cik":"0001587972","reported_name":"Crowley John J","relationship":{"officer":true,"officer_title":"SVP, Chief Accounting Officer"}}],"security":"Common Stock","published_at":"2016-10-04T14:52:56.000Z","date":"2016-10-01","kind":"tax_withholding","acquired":false,"shares":284,"price":83.34,"value":23668.56,"ownership":{"direct":true},"balance_after":5599,"source":{"system":"sec-edgar","filing":"0001127602-16-063835","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100682/000112760216063835/form4.xml","form_type":"4"}}]}